Opinion|Videos|March 8, 2025
Challenges for Making a Timely GPP Diagnosis
Panelists discuss the biggest challenges dermatologists face in diagnosing generalized pustular psoriasis (GPP), focusing on the heterogeneity of patient presentations and how this complicates the diagnosis. They also explore how the relative rarity of GPP, compared with other psoriatic conditions, contributes to delays in diagnosis and treatment. They also examine the impact of misdiagnosis or delayed diagnosis on patient outcomes.
Advertisement
Video content above is prompted by the following:
Episodes in this series
- What are some of the biggest challenges dermatologists face when diagnosing GPP?
- How does the heterogeneity of patient presentation complicate diagnosis?
- Compared with other psoriatic conditions, how does the relative rarity of GPP contribute to delays in diagnosis and treatment?
How can misdiagnosis or delayed diagnosis affect patient outcomes?
Advertisement
Related to this article
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.
In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
Advertisement
Advertisement
Trending on HCPLive
1
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
2
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
3
Rezpegaldesleukin Hair Regrowth Climbs Through 1 Year in AA: David Rosmarin, MD
4
EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know
5